Endometriosis
-
Allara Snags $10M to Scale Its Platform for Women’s Chronic Hormonal Conditions
Allara raised $10 million in a Series A funding round led by GV. The startup offers membership-based virtual services to treat women’s chronic hormonal conditions, such as PCOS and endometriosis. CEO Rachel Blank — former executive at Ro and investor at General Catalyst — founded the company partly due to the difficulty she experienced arriving at her own PCOS diagnosis.
-
Organon makes another women’s health move with deal for endometriosis-focused Forendo
Organon’s proposed acquisition of Forendo Pharma is the company’s third since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Artificial Intelligence, BioPharma, Health Tech
Chugai, Biofourmis partner on DTx for pain monitoring
The companies will test Biofourmis’ sensor and artificial intelligence system in a clinical trial of more than 120 women with endometriosis.
-
Women’s health drugmaker Meditrina seeks fresh funding
Meditrina, which is based in Ann Arbor, Michigan, is using patents from AstraZeneca to treat women’s health issues including endometriosis and uterine fibroids, which are abnormal growths or tumors that can cause pain and infertility. The company has completed Phase II trials on its two drugs – MPI-676 and MPI-674 – which treat endometriosis and abnormal uterine bleeding, respectively.